

### **In the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### ***Listing of Claims***

1. (Currently amended) A pharmaceutical composition comprising as active ingredients a combination of at least one antihistamine, or a stereoisomer, a pharmaceutically acceptable salt, ~~solvate~~ or physiologically functional derivative thereof, and ciclesonide, or a pharmaceutically acceptable salt of ciclesonide, an epimer of ciclesonide, ~~a solvate of ciclesonide,~~ or a physiologically functional derivative of ciclesonide ~~or a solvate thereof~~, and a pharmaceutically acceptable carrier and/or one or more excipients, wherein said pharmaceutical composition has an osmotic pressure of less than 290 mOsm.

2. (Canceled)

3. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 ~~[[2]]~~, wherein said osmotic pressure is 150 mOsm or less.

4. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 ~~[[2]]~~, wherein said osmotic pressure is 60 mOsm or less.

5. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 ~~[[2]]~~, wherein said osmotic pressure is 40 mOsm or less.

6. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 **[[2]]**, wherein said osmotic pressure is 20 mOsm or less.

7. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 **[[2]]**, further comprising an osmotic pressure-controlling agent.

8. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 **[[2]]**, wherein said water-insoluble and/or water-low soluble substance is a cellulose.

9. (Original) The pharmaceutical composition for application to the mucosa according to claim 8, wherein said cellulose is microcrystalline cellulose.

10. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 **[[2]]**, wherein said one or more water-insoluble and/or water-low soluble substances is/are present as solid particles in an aqueous medium.

11. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 **[[2]]**, further comprising a water-soluble polymer substance.

12. (Previously Amended) The pharmaceutical composition for application to the mucosa according to claim 11, wherein a combination of said water-insoluble substance and water-soluble polymer is present which is microcrystalline cellulose and carboxymethyl cellulose sodium.

13. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 ~~[[2]]~~, further comprising a surfactant and/or a wetting agent.

14. (Currently amended) The pharmaceutical composition for application to the mucosa according to claim 1 ~~[[2]]~~, wherein said mucosa is nasal mucosa.

15. (Currently amended) The pharmaceutical composition according to claim 1, wherein the antihistamine is selected from the group consisting of (E)-6-[(E)-3-(1-pyrrolidiny)-1-p-tolylpropenyl]-2-pyridineacrylic acid (ACRIVASTINE), 6,11-Dihydro-11-(1-methyl-4-piperidyliden)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine (AZATADINE), 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)phthalazinone (AZELASTINE), (+)-(S)-4-[4-[1-(4-chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]-butanoic acid (BEPOTASTINE), (+/-)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid (CETIRIZINE), (+)-2-[2-[(p-Chlor-alpha-methyl-alpha-phenylbenzyl)oxy]-ethyl]-1-methylpyrrolidin (CLEMASTINE), 8-chloro-6,11-dihydro-11-(4-piperidylidene-5H-benzo[5,6]-cyclohepta-[1,2-b]pyridine (DESLO RATADINE), [3-(4-Chlorophenyl)-3-pyridin-2-yl-propyl]-dimethylamine (DEXCHLORPHENIRAMINE), 4'-tert-butyl-4-[4-(diphenylmethoxy)-piperidino]butyrophenone (EBASTINE), [2-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-acetic acid (EFLETIRIZINE), 1-(2-ethoxyethyl)-2-hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-benzimidazole (EMEDASTINE), 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine (EPINASTINE), (+/-)-p-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]-butyl]-alpha-methylhydratropic acid (FEXOFENADINE), 3-[4-(8-fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)-piperidin-1-yl]propionic acid (Research Code HSR-609), (-)-(3S,4R)-1-[cis-4-cyano-4-(p-fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipectic acid (LEVOCABASTINE), [2-[4-[(R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid (LEVOCETIRIZINE), ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate (LORATADINE), 2[N-[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl]-4-piperidinyl]-N-methyl-amino]pyrimidin-

4(3H)-one (MIZOLASTINE), 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1H-benzimidazole (NORASTMIZOLE), 3-(10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5-ylidene)-N-methyl-1-propanamine (NORTRIPTYLINE), 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (PEMIROLAST), 8-chloro-11-[1-(5-methylpyridin-3-ylmethyl)-piperidin-4-ylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (RUPATADINE), 1-[2-[(p-chloro-alpha-methyl-alpha-phenylbenzyl)-oxy]ethyl]hexahydro-1H-azepine (SETASTINE), S-(7-carboxy-4-hexyl-9-oxoxanthen-2-yl)-S-methylsulfoximine (SUDEXANOX), 1-(p-tert-butyl-phenyl)-4-[4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl]-butanol (TERFENADINE), N-benzyl-N,N'-dimethyl-N-(2-pyridyl)-ethylenediamine (TRIPELENAMINE), 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1H-benzimidazole (TECASTEMIZOLE), stereoisomers thereof, pharmaceutically acceptable salts thereof, ~~solvates thereof~~, and mixtures thereof.

16. (Currently amended) The pharmaceutical composition according to claim 1, wherein the antihistamine is selected from the group consisting of azelastine, levocabastine, and salts thereof ~~and solvates thereof~~.

17. (Canceled)

18. (Currently amended) A method for the treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising at least one antihistamine or a pharmaceutically acceptable salt, ~~solvate~~, or physiologically functional derivative thereof, and ciclesonide or a pharmaceutically acceptable salt, ~~solvate~~, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier and/or one or more excipients.

19. (Previously presented) The pharmaceutical composition according to claim 1, wherein said epimer of ciclesonide is [11 $\beta$ ,16 $\alpha$ (S)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-

dien-3,20-dion and is present in any mixing ratio with ciclesonide, [11 $\beta$ ,16 $\alpha$ (R)]-16,17-[(cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-dien-3,20-dion.

20. (Previously presented) The method of claim 18, wherein said mammal is a human.